{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:51:39Z","timestamp":1775566299164,"version":"3.50.1"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Imam Mohammad Ibn Saud Islamic University","award":["IMSIU-DDRSP2501"],"award-info":[{"award-number":["IMSIU-DDRSP2501"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11752-8","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:16:08Z","timestamp":1775560568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T cell therapy in breast cancer management: expanding horizon and overcoming challenges beyond hematologic cancers"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3110-2759","authenticated-orcid":false,"given":"Kavya P.","family":"Parekh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4237-9464","authenticated-orcid":false,"given":"Fahad T.","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8886-6101","authenticated-orcid":false,"given":"Dhvani D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2848-2932","authenticated-orcid":false,"given":"Omar Awad","family":"Alsaidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-4541","authenticated-orcid":false,"given":"Bhupendra G.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4007-4023","authenticated-orcid":false,"given":"Sami I.","family":"Alzarea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3581-7123","authenticated-orcid":false,"given":"Ala Meshal","family":"Aljehani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-0986","authenticated-orcid":false,"given":"Mehul R.","family":"Chorawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"4","key":"11752_CR1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ijc.34740","volume":"154","author":"Z Yu","year":"2024","unstructured":"Yu Z, Bai X, Zhou R, Ruan G, Guo M, Han W et al (2024) Differences in the incidence and mortality of digestive cancer between Global Cancer Observatory 2020 and Global Burden of Disease 2019. Int J Cancer 154(4):615\u2013625","journal-title":"Int J Cancer"},{"issue":"8","key":"11752_CR2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi\u00f1eros M et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941\u20131953","journal-title":"Int J Cancer"},{"key":"11752_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.breast.2022.07.006","volume":"65","author":"S Mertz","year":"2022","unstructured":"Mertz S, Benjamin C, Girvalaki C, Cardone A, Gono P, May SG et al (2022) Progression-free survival and quality of life in metastatic breast cancer: the patient perspective. The Breast 65:84\u201390","journal-title":"The Breast"},{"key":"11752_CR4","doi-asserted-by":"crossref","unstructured":"Orrantia-Borunda E, Anchondo-Nu\u00f1ez P, Acu\u00f1a-Aguilar LE, G\u00f3mez-Valles FO, Ram\u00edrez-Valdespino CA. (2022) Subtypes of breast cancer. Breast Cancer [Internet].","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"issue":"1","key":"11752_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-8-118","volume":"8","author":"X Yang","year":"2007","unstructured":"Yang X, Sun X (2007) Meta-analysis of several gene lists for distinct types of cancer: a simple way to reveal common prognostic markers. BMC Bioinform 8(1):118","journal-title":"BMC Bioinform"},{"issue":"4","key":"11752_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040916","volume":"12","author":"E Vagia","year":"2020","unstructured":"Vagia E, Mahalingam D, Cristofanilli M (2020) The landscape of targeted therapies in TNBC. Cancers 12(4):916","journal-title":"Cancers"},{"issue":"4","key":"11752_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13040344","volume":"13","author":"M Palma","year":"2025","unstructured":"Palma M (2025) Advancing breast cancer treatment: the role of immunotherapy and cancer vaccines in overcoming therapeutic challenges. Vaccines 13(4):344","journal-title":"Vaccines"},{"issue":"21","key":"11752_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115688","volume":"24","author":"AC Uscanga-Palomeque","year":"2023","unstructured":"Uscanga-Palomeque AC, Ch\u00e1vez-Escamilla AK, Alvizo-B\u00e1ez CA, Saavedra-Alonso S, Terrazas-Armend\u00e1riz LD, Tamez-Guerra RS et al (2023) CAR-T cell therapy: from the shop to cancer therapy. Int J Mol Sci 24(21):15688","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11752_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2378543","volume":"20","author":"D Goyco Vera","year":"2024","unstructured":"Goyco Vera D, Waghela H, Nuh M, Pan J, Lulla P (2024) Approved CAR-T therapies have reproducible efficacy and safety in clinical practice. Hum Vaccin Immunother 20(1):2378543","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"11752_CR10","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C (2025) From concept to cure: the evolution of CAR-T cell therapy. Mol Ther 33(5):2123\u20132140","journal-title":"Mol Ther"},{"key":"11752_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1385571","volume":"15","author":"Z Niu","year":"2024","unstructured":"Niu Z, Wu J, Zhao Q, Zhang J, Zhang P, Yang Y (2024) CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Front Immunol 15:1385571","journal-title":"Front Immunol"},{"key":"11752_CR12","doi-asserted-by":"publisher","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, Aghebati-Maleki L et al (2023) The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front Immunol 14:1113882","journal-title":"Front Immunol"},{"issue":"1","key":"11752_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03615-8","volume":"25","author":"HE Marei","year":"2025","unstructured":"Marei HE, Bedair K, Hasan A, Al-Mansoori L, Caratelli S, Sconocchia G et al (2025) Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer. Cancer Cell Int 25(1):3","journal-title":"Cancer Cell Int"},{"key":"11752_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102868","volume":"133","author":"G Buono","year":"2025","unstructured":"Buono G, Capozzi M, Caputo R, Di Lauro V, Cianniello D, Piezzo M et al (2025) CAR-T cell therapy for breast cancer: current status and future perspective. Cancer Treat Rev 133:102868","journal-title":"Cancer Treat Rev"},{"key":"11752_CR15","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.948125","volume":"31","author":"DV Parums","year":"2025","unstructured":"Parums DV (2025) A review of CAR T cells and adoptive T-Cell therapies in lymphoid and solid organ malignancies. Med Sci Monit 31:e948125","journal-title":"Med Sci Monit"},{"key":"11752_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.797440","volume":"10","author":"A Alnefaie","year":"2022","unstructured":"Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-Sanea MM et al (2022) Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions. Front bioeng biotechnol 10:797440","journal-title":"Front bioeng biotechnol"},{"issue":"8","key":"11752_CR17","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","volume":"3","author":"F Korell","year":"2022","unstructured":"Korell F, Berger TR, Maus MV (2022) Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes. Med 3(8):538\u2013564","journal-title":"Med"},{"issue":"1","key":"11752_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/1804038","volume":"2024","author":"G Gezehagn Kussia","year":"2024","unstructured":"Gezehagn Kussia G, Tessema TS (2024) The potential of single\u2010chain variable fragment antibody: role in future therapeutic and diagnostic biologics. J Immunol Res 2024(1):1804038","journal-title":"J Immunol Res"},{"issue":"5","key":"11752_CR19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L et al (2020) Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov 10(5):702\u2013723","journal-title":"Cancer Discov"},{"issue":"4","key":"11752_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):69","journal-title":"Blood Cancer J"},{"issue":"11","key":"11752_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell KM, Kochenderfer JN (2021) A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol 18(11):715\u2013727","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"11752_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003354","volume":"9","author":"E Roselli","year":"2021","unstructured":"Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K et al (2021) 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J Immunother Cancer 9(10):e003354","journal-title":"J Immunother Cancer"},{"issue":"5","key":"11752_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051182","volume":"9","author":"K Fujiwara","year":"2020","unstructured":"Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N (2020) Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold. Cells 9(5):1182","journal-title":"Cells"},{"key":"11752_CR24","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.omto.2021.11.003","volume":"23","author":"A Bister","year":"2021","unstructured":"Bister A, Ibach T, Haist C, Smorra D, Roellecke K, Wagenmann M et al (2021) A novel CD34-derived hinge for rapid and efficient detection and enrichment of CAR T cells. Molecular Therapy-Oncolytics 23:534\u2013546","journal-title":"Molecular Therapy-Oncolytics"},{"issue":"1","key":"11752_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-06770-w","volume":"7","author":"V Folimonova","year":"2024","unstructured":"Folimonova V, Chen X, Negi H, Schwieters CD, Li J, Byrd RA et al (2024) CD28 hinge used in chimeric antigen receptor [CAR] T-cells exhibits local structure and conformational exchange amidst global disorder. Communications Biol 7(1):1072","journal-title":"Communications Biol"},{"issue":"4","key":"11752_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/mt.2014.208","volume":"23","author":"M Jonnalagadda","year":"2015","unstructured":"Jonnalagadda M, Mardiros A, Urak R, Wang X, Hoffman LJ, Bernanke A et al (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23(4):757\u2013768","journal-title":"Mol Ther"},{"issue":"2","key":"11752_CR27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","volume":"221","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY (2024) CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med 221(2):e20230903","journal-title":"J Exp Med"},{"key":"11752_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C (2017) Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev 4:92\u2013101","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"11752_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000325","volume":"8","author":"L Minute","year":"2020","unstructured":"Minute L, Teijeira A, Sanchez-Paulete AR, Ochoa MC, Alvarez M, Otano I et al (2020) Cellular cytotoxicity is a form of immunogenic cell death. J Immunother Cancer 8(1):e000325","journal-title":"J Immunother Cancer"},{"key":"11752_CR30","doi-asserted-by":"publisher","first-page":"1688995","DOI":"10.3389\/fimmu.2025.1688995","volume":"16","author":"T Frlic","year":"2025","unstructured":"Frlic T, Pavlin MJ (2025) Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy. Front immunol 16:1688995","journal-title":"Front immunol"},{"issue":"3","key":"11752_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030655","volume":"10","author":"P Guha","year":"2022","unstructured":"Guha P, Heatherton KR, O\u2019Connell KP, Alexander IS, Katz SC (2022) Assessing the future of solid tumor immunotherapy. Biomedicines 10(3):655","journal-title":"Biomedicines"},{"issue":"1","key":"11752_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.36401\/JIPO-22-7","volume":"6","author":"SA Srour","year":"2023","unstructured":"Srour SA, Akin S (2023) Chimeric antigen receptor T-cell therapy for solid tumors: the past and the future. J Immunother Precis Oncol 6(1):19\u201330","journal-title":"J Immunother Precis Oncol"},{"key":"11752_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121565","volume":"14","author":"PM Nanjireddy","year":"2023","unstructured":"Nanjireddy PM, Olejniczak SH, Buxbaum NP (2023) Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes. Front Immunol 14:1121565","journal-title":"Front Immunol"},{"issue":"5","key":"11752_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A (2023) CAR-T therapies in solid tumors: opportunities and challenges. Curr Oncol Rep 25(5):479\u2013489","journal-title":"Curr Oncol Rep"},{"key":"11752_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21776","author":"C Wang","year":"2023","unstructured":"Wang C, Wang J, Che S, Zhao H (2023) CAR-T cell therapy for hematological malignancies: History, status and promise. Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21776","journal-title":"Heliyon"},{"issue":"1","key":"11752_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03938-0","volume":"25","author":"J Zhu","year":"2025","unstructured":"Zhu J, Zhou J, Tang Y, Huang R, Lu C, Qian K et al (2025) Advancements and challenges in CAR-T cell therapy for solid tumors: a comprehensive review of antigen targets, strategies, and future directions. Cancer Cell Int 25(1):313","journal-title":"Cancer Cell Int"},{"issue":"6","key":"11752_CR37","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.70120","volume":"18","author":"Y-H Yang","year":"2022","unstructured":"Yang Y-H, Liu J-W, Lu C, Wei J-F (2022) CAR-T cell therapy for breast cancer: from basic research to clinical application. Int J Biol Sci 18(6):2609","journal-title":"Int J Biol Sci"},{"issue":"3","key":"11752_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030571","volume":"14","author":"JA Kyte","year":"2022","unstructured":"Kyte JA (2022) Strategies for improving the efficacy of CAR T cells in solid cancers. Cancers 14(3):571","journal-title":"Cancers"},{"issue":"5","key":"11752_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","volume":"2","author":"M Abou-el-Enein","year":"2021","unstructured":"Abou-el-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P et al (2021) Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood cancer discovery 2(5):408\u2013422","journal-title":"Blood cancer discovery"},{"issue":"2","key":"11752_CR40","volume":"9","author":"B Liu","year":"2019","unstructured":"Liu B, Yan L, Zhou M (2019) Target selection of CAR T cell therapy in accordance with the TME for solid tumors. Am J Cancer Res 9(2):228","journal-title":"Am J Cancer Res"},{"key":"11752_CR41","doi-asserted-by":"publisher","DOI":"10.4137\/BIC.S38542","volume":"8","author":"MC Boonstra","year":"2016","unstructured":"Boonstra MC, De Geus SW, Prevoo HA, Hawinkels LJ, Van De Velde CJ, Kuppen PJ et al (2016) Selecting targets for tumor imaging: an overview of cancer-associated membrane proteins. Biomark cancer 8:BIC. S38542","journal-title":"Biomark cancer"},{"issue":"1","key":"11752_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-025-01085-w","volume":"31","author":"Z Khosroabadi","year":"2025","unstructured":"Khosroabadi Z, Azaryar S, Dianat-Moghadam H, Amoozgar Z, Sharifi M (2025) Single cell RNA sequencing improves the next generation of approaches to AML treatment: challenges and perspectives. Mol Med 31(1):33","journal-title":"Mol Med"},{"issue":"8","key":"11752_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj6251","volume":"10","author":"L Lu","year":"2024","unstructured":"Lu L, Xie M, Yang B, Zhao W-b, Cao J (2024) Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control. Sci Adv 10(8):eadj6251","journal-title":"Sci Adv"},{"issue":"7","key":"11752_CR44","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1074\/jbc.REV119.009457","volume":"295","author":"JM Westerfield","year":"2020","unstructured":"Westerfield JM, Barrera FN (2020) Membrane receptor activation mechanisms and transmembrane peptide tools to elucidate them. J Biol Chem 295(7):1792\u20131814","journal-title":"J Biol Chem"},{"issue":"2","key":"11752_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","volume":"3","author":"M Hudecek","year":"2015","unstructured":"Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C et al (2015) The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 3(2):125\u2013135","journal-title":"Cancer Immunol Res"},{"issue":"21","key":"11752_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz3223","volume":"6","author":"S Lindner","year":"2020","unstructured":"Lindner S, Johnson S, Brown C, Wang L (2020) Chimeric antigen receptor signaling: Functional consequences and design implications. Sci Adv 6(21):eaaz3223","journal-title":"Sci Adv"},{"issue":"9","key":"11752_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091303","volume":"12","author":"MM Honikel","year":"2022","unstructured":"Honikel MM, Olejniczak SH (2022) Co-stimulatory receptor signaling in CAR-T cells. Biomolecules 12(9):1303","journal-title":"Biomolecules"},{"issue":"8","key":"11752_CR48","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","volume":"2","author":"MC Milone","year":"2021","unstructured":"Milone MC, Xu J, Chen S-J, Collins MA, Zhou J, Powell DJ Jr et al (2021) Engineering-enhanced CAR T cells for improved cancer therapy. Nature cancer 2(8):780\u2013793","journal-title":"Nature cancer"},{"issue":"4","key":"11752_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.101121","volume":"11","author":"M Khoshandam","year":"2024","unstructured":"Khoshandam M, Soltaninejad H, Hamidieh AA, Hosseinkhani SJG (2024) CRISPR, CAR-T, and NK: Current applications and future perspectives. Genes & Diseases 11(4):101121","journal-title":"Genes & Diseases"},{"issue":"1","key":"11752_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00602-z","volume":"12","author":"P Song","year":"2024","unstructured":"Song P, Zhang Q, Xu Z, Shi Y, Jing R, Luo DJ (2024) CRISPR\/Cas-based CAR-T cells: production and application. Biomark Res 12(1):54","journal-title":"Biomark Res"},{"issue":"7","key":"11752_CR51","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/bit.24890","volume":"110","author":"N Sun","year":"2013","unstructured":"Sun N, Zhao HJ (2013) Transcription activator\u2010like effector nucleases [TALENs]: a highly efficient and versatile tool for genome editing. Biotechnol Bioeng 110(7):1811\u20131821","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"11752_CR52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3486","volume":"14","author":"JK Joung","year":"2013","unstructured":"Joung JK, Sander JD (2013) TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14(1):49\u201355","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"11752_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70067","volume":"6","author":"H Yin","year":"2025","unstructured":"Yin H, Wei XJ (2025) The design of retroviral vectors used in the CAR\u2010T products, risk management, and future perspective. MedComm 6(2):e70067","journal-title":"MedComm"},{"issue":"8","key":"11752_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/v13081528","volume":"13","author":"RP Labb\u00e9","year":"2021","unstructured":"Labb\u00e9 RP, Vessillier S, Rafiq QA (2021) Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives. Viruses 13(8):1528","journal-title":"Viruses"},{"issue":"11","key":"11752_CR55","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/mt.2009.172","volume":"17","author":"M Bosticardo","year":"2009","unstructured":"Bosticardo M, Ghosh A, Du Y, Jenkins NA, Copeland NG, Candotti F (2009) Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells. Mol Ther 17(11):1910\u20131918","journal-title":"Mol Ther"},{"issue":"10","key":"11752_CR56","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1073\/pnas.83.10.3194","volume":"83","author":"S-F Yu","year":"1986","unstructured":"Yu S-F, Von R\u00fcden T, Kantoff PW, Garber C, Seiberg M, R\u00fcther U et al (1986) Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci 83(10):3194\u20133198","journal-title":"Proc Natl Acad Sci"},{"key":"11752_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519671","volume":"15","author":"Y Kong","year":"2025","unstructured":"Kong Y, Li J, Zhao X, Wu Y, Chen L (2025) CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. Front immunol 15:1519671","journal-title":"Front immunol"},{"issue":"5","key":"11752_CR58","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS (2019) Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36(5):471\u2013482","journal-title":"Cancer Cell"},{"issue":"1","key":"11752_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma DJ et al (2023) Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther 8(1):320","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"11752_CR60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/PPO.0000000000000511","volume":"27","author":"N Watanabe","year":"2021","unstructured":"Watanabe N, Mamonkin MJ (2021) Off-the-shelf chimeric antigen receptor T cells: how do we get there? Cancer J 27(2):176\u2013181","journal-title":"Cancer J"},{"key":"11752_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122683","volume":"348","author":"Y Metanat","year":"2024","unstructured":"Metanat Y, Viktor P, Amajd A, Kaur I, Hamed AM, Al-Abadi NKA et al (2024) The paths toward non-viral CAR-T cell manufacturing: a comprehensive review of state-of-the-art methods. Life Sci 348:122683","journal-title":"Life Sci"},{"issue":"4","key":"11752_CR62","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3343\/alm.2023.0382","volume":"44","author":"NK Lee","year":"2024","unstructured":"Lee NK, Chang JW (2024) Manufacturing cell and gene therapies: challenges in clinical translation. Ann Lab Med 44(4):314\u2013323","journal-title":"Ann Lab Med"},{"key":"11752_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189455","author":"L von Bornemann Fl\u00f8e","year":"2025","unstructured":"von Bornemann Fl\u00f8e L, Pedersen MG, M\u00f8ller BK (2025) Animal models in preclinical evaluation of CAR-T cell therapy: Advantages and limitations. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189455","journal-title":"Biochimica et Biophysica Acta (BBA)-Reviews on Cancer."},{"issue":"6","key":"11752_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011698","volume":"13","author":"D Andreu-Sanz","year":"2025","unstructured":"Andreu-Sanz D, Gregor L, Carlini E, Scarcella D, Marr C, Kobold SJ (2025) Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis. J Immunother Cancer 13(6):e011698","journal-title":"J Immunother Cancer"},{"issue":"8","key":"11752_CR65","first-page":"903","volume":"22","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Li Y, Jing X, Weng L, Liu X, Liu Q et al (2025) Organoid models in oncology: advancing precision cancer therapy and vaccine development 22(8):903\u2013927","journal-title":"Organoid models in oncology: advancing precision cancer therapy and vaccine development"},{"key":"11752_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878209","volume":"13","author":"G L\u00f3pez-Cantillo","year":"2022","unstructured":"L\u00f3pez-Cantillo G, Urue\u00f1a C, Camacho BA, Ram\u00edrez-Segura CJ (2022) CAR-T cell performance: how to improve their persistence? Front Immunol 13:878209","journal-title":"Front Immunol"},{"issue":"6","key":"11752_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063154","volume":"23","author":"X Si","year":"2022","unstructured":"Si X, Xiao L, Brown CE, Wang D (2022) Preclinical evaluation of CAR T cell function: in vitro and in vivo models. Int J Mol Sci 23(6):3154","journal-title":"Int J Mol Sci"},{"key":"11752_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2025.1607488","volume":"13","author":"X Jiang","year":"2025","unstructured":"Jiang X, Yan-Ran W, Pin-Ru D, Shi-Yi Q, Haitao J (2025) Organoids in cancer therapy: a comprehensive review. Front Bioeng Biotechnol 13:1607488","journal-title":"Front Bioeng Biotechnol"},{"key":"11752_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.619236","volume":"11","author":"SA Mian","year":"2021","unstructured":"Mian SA, Anjos-Afonso F, Bonnet D (2021) Advances in human immune system mouse models for studying human hematopoiesis and cancer immunotherapy. Front Immunol 11:619236","journal-title":"Front Immunol"},{"issue":"1","key":"11752_CR70","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/jnt3010003","volume":"3","author":"MMH Pial","year":"2022","unstructured":"Pial MMH, Tomitaka A, Pala N, Roy U (2022) Implantable devices for the treatment of breast cancer. J Nanotheranostics 3(1):19\u201338","journal-title":"J Nanotheranostics"},{"issue":"1","key":"11752_CR71","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, Dewanjee S, Li Y, Jha NK, Chen Z-S, Kumar A et al (2023) Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer 22(1):105","journal-title":"Mol Cancer"},{"key":"11752_CR72","doi-asserted-by":"crossref","unstructured":"Sakamoto K, Schmidt JW, Wagner K-U. (2015) Mouse models of breast cancer. Mouse Models of Cancer: Methods and Protocols: Springer. p. 47\u201371.","DOI":"10.1007\/978-1-4939-2297-0_3"},{"issue":"7","key":"11752_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071987","volume":"15","author":"MF Mercogliano","year":"2023","unstructured":"Mercogliano MF, Bruni S, Mauro FL, Schillaci RJ (2023) Emerging targeted therapies for HER2-positive breast cancer. Cancers 15(7):1987","journal-title":"Cancers"},{"key":"11752_CR74","doi-asserted-by":"crossref","unstructured":"Rodriguez-Garcia A, Watanabe K, Guedan S. (2019) Analysis of antitumor effects of CAR-T cells in mice with solid tumors. Chimeric Antigen Receptor T Cells: Development and Production: Springer; 2019. p. 251\u201371.","DOI":"10.1007\/978-1-0716-0146-4_19"},{"issue":"12","key":"11752_CR75","doi-asserted-by":"publisher","first-page":"e007426","DOI":"10.1136\/jitc-2023-007426","volume":"11","author":"D Bassan","year":"2023","unstructured":"Bassan D, Weinberger L, Yi J, Kim T, Weist MR, Adams GB et al (2023) HER2 and HLA-A* 02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity. J immunotherapy cancer. 11(12):e007426","journal-title":"J immunotherapy cancer."},{"key":"11752_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1053120","volume":"13","author":"Y Qin","year":"2022","unstructured":"Qin Y, Xu G (2022) Enhancing CAR T-cell therapies against solid tumors: mechanisms and reversion of resistance. Front Immunol 13:1053120","journal-title":"Front Immunol"},{"issue":"8","key":"11752_CR77","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.3390\/ijms25084170","volume":"25","author":"J Rojas-Quintero","year":"2024","unstructured":"Rojas-Quintero J, D\u00edaz MP, Palmar J, Galan-Freyle NJ, Morillo V, Escalona D et al (2024) Car T cells in solid tumors: overcoming obstacles. Int J molecular Sci 25(8):4170","journal-title":"Int J molecular Sci"},{"issue":"5","key":"11752_CR78","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.apsb.2020.10.020","volume":"11","author":"H Dana","year":"2021","unstructured":"Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER et al (2021) CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharmaceutica Sinica B. 11(5):1129\u20131147","journal-title":"Acta Pharmaceutica Sinica B."},{"issue":"7","key":"11752_CR79","first-page":"1979","volume":"10","author":"M Huang","year":"2020","unstructured":"Huang M, Deng J, Gao L, Zhou JJ (2020) Innovative strategies to advance CAR T cell therapy for solid tumors. Am j cancer res 10(7):1979","journal-title":"Am j cancer res"},{"issue":"1","key":"11752_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02476-1","volume":"41","author":"K Asleh","year":"2022","unstructured":"Asleh K, Riaz N, Nielsen TO (2022) Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. J Exp Clin Cancer Res 41(1):265","journal-title":"J Exp Clin Cancer Res"},{"key":"11752_CR81","doi-asserted-by":"publisher","first-page":"1018786","DOI":"10.3389\/fimmu.2022.1018786","volume":"13","author":"F Nasiri","year":"2022","unstructured":"Nasiri F, Kazemi M, Mirarefin SMJ, Mahboubi Kancha M, Ahmadi Najafabadi M, Salem F et al (2022) CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. Front Immunol 13:1018786","journal-title":"Front Immunol"},{"issue":"3","key":"11752_CR82","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17(3):147\u2013167","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"11752_CR83","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","volume":"44","author":"S Imani","year":"2025","unstructured":"Imani S, Farghadani R, Roozitalab G, Maghsoudloo M, Emadi M, Moradi A et al (2025) Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy. J Exp Clinical Cancer Res 44(1):131","journal-title":"J Exp Clinical Cancer Res"},{"issue":"1","key":"11752_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-025-02400-z","volume":"24","author":"K Mandal","year":"2025","unstructured":"Mandal K, Barik GK, Santra MK (2025) Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions. Mol Cancer 24(1):1\u201352","journal-title":"Mol Cancer"},{"key":"11752_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1615760","volume":"16","author":"A Morva","year":"2025","unstructured":"Morva A, Arroyo AB, Andreeva L, Tapia-Abell\u00e1n A, Luengo-Gil G (2025) Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review. Front Immunol 16:1615760","journal-title":"Front Immunol"},{"key":"11752_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.925985","volume":"13","author":"MP Jogalekar","year":"2022","unstructured":"Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn B-C (2022) CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol 13:925985","journal-title":"Front Immunol"},{"issue":"13","key":"11752_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133476","volume":"15","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, Li S, Liu M, Chen C, Zhang L, Zhou D (2023) Fine-tuning through generations: advances in structure and production of CAR-T therapy. Cancers 15(13):3476","journal-title":"Cancers"},{"issue":"10","key":"11752_CR88","volume":"14","author":"ML Davila","year":"2016","unstructured":"Davila ML, Brentjens RJ (2016) CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. JCaih, H o 14(10):802","journal-title":"JCaih, H o"},{"issue":"1","key":"11752_CR89","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 [HER2] in cancers: overexpression and therapeutic implications. Molecular biol int 2014(1):852748","journal-title":"Molecular biol int"},{"issue":"3","key":"11752_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/diseases10030060","volume":"10","author":"AK Mishra","year":"2022","unstructured":"Mishra AK, Ali A, Dutta S, Banday S, Malonia SK (2022) Emerging trends in immunotherapy for cancer. Diseases 10(3):60","journal-title":"Diseases"},{"issue":"1","key":"11752_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01016-2","volume":"9","author":"US Grewal","year":"2025","unstructured":"Grewal US, Kurzrock R (2025) Mucin-1: a promising pan-cancer therapeutic target. NPJ Precis Oncol 9(1):218","journal-title":"NPJ Precis Oncol"},{"issue":"9","key":"11752_CR92","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.7150\/thno.98178","volume":"14","author":"X Liu","year":"2024","unstructured":"Liu X, Ma L, Li J, Sun L, Yang Y, Liu T et al (2024) Trop2-targeted therapies in solid tumors: advances and future directions. Theranostics 14(9):3674\u20133692","journal-title":"Theranostics"},{"issue":"5","key":"11752_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1135","volume":"9","author":"L Xia","year":"2020","unstructured":"Xia L, Zheng Z, Liu J, Chen Y, Ding J, Xia N et al (2020) EGFR\u2010targeted CAR\u2010T cells are potent and specific in suppressing triple\u2010negative breast cancer both in vitro and in vivo. Clinical translational immunol 9(5):e1135","journal-title":"Clinical translational immunol"},{"key":"11752_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116203","volume":"171","author":"J-W Cui","year":"2024","unstructured":"Cui J-W, Li Y, Yang Y, Yang H-K, Dong J-M, Xiao Z-H et al (2024) Tumor immunotherapy resistance: Revealing the mechanism of PD-1\/PD-L1-mediated tumor immune escape. Biomed Pharmacother 171:116203","journal-title":"Biomed Pharmacother"},{"key":"11752_CR95","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3389\/fonc.2019.00510","volume":"9","author":"R El Sayed","year":"2019","unstructured":"El Sayed R, El Jamal L, El Iskandarani S, Kort J, Salam MA, Assi H (2019) Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials. Front Oncol 9:510","journal-title":"Front Oncol"},{"key":"11752_CR96","doi-asserted-by":"publisher","first-page":"1564642","DOI":"10.3389\/or.2025.1564642","volume":"19","author":"N Kim","year":"2025","unstructured":"Kim N, Lukong KE (2025) Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action. Oncol Rev 19:1564642","journal-title":"Oncol Rev"},{"key":"11752_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.824208","volume":"12","author":"X Zheng","year":"2022","unstructured":"Zheng X, Liu X, Lei Y, Wang G, Liu M (2022) Glypican-3: A novel and promising target for the treatment of hepatocellular carcinoma. Front Oncol 12:824208","journal-title":"Front Oncol"},{"key":"11752_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2024.100204","volume":"7","author":"EEJ Iweala","year":"2024","unstructured":"Iweala EEJ, Amuji DN, Oluwajembola AM, Ugbogu EA (2024) Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies. Curr Res Pharmacol Drug Discov 7:100204","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"4","key":"11752_CR99","first-page":"813","volume":"2","author":"V Lorusso","year":"2008","unstructured":"Lorusso V (2008) Bevacizumab in the treatment of HER2-negative breast cancer. Biologics: Targets Ther 2(4):813\u2013821","journal-title":"Biologics: Targets Ther"},{"issue":"1","key":"11752_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02005-w","volume":"27","author":"F Wang","year":"2025","unstructured":"Wang F, Li W, Han G, Xie J, Bai X (2025) A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer. Breast Cancer Res 27(1):47","journal-title":"Breast Cancer Res"},{"issue":"15","key":"11752_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/cells14151209","volume":"14","author":"S Mielcarska","year":"2025","unstructured":"Mielcarska S, Kot A, Dawidowicz M, Kula A, Sobk\u00f3w P, K\u0142aczka D et al (2025) B7-H3 in Cancer Immunotherapy\u2014Prospects and Challenges: A Review of the Literature. Cells 14(15):1209","journal-title":"Cells"},{"key":"11752_CR102","doi-asserted-by":"crossref","unstructured":"Brudno JN, Maus MV, Hinrichs CSJJ. (2024) CAR T cells and T-cell therapies for cancer: A translational science review.","DOI":"10.1001\/jama.2024.19462"},{"issue":"1","key":"11752_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen T, Wang M, Chen Y, Liu Y (2024) Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int 24(1):133","journal-title":"Cancer Cell Int"},{"key":"11752_CR104","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LAK Fonkoua","year":"2022","unstructured":"Fonkoua LAK, Sirpilla O, Sakemura R, Siegler EL, Kenderian SSJMT-O (2022) CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol Therapy-Oncolytics 25:69\u201377","journal-title":"Mol Therapy-Oncolytics"},{"key":"11752_CR105","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","volume":"58","author":"RJ Davis","year":"2016","unstructured":"Davis RJ, Van Waes C, Allen CT (2016) Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol 58:59\u201370","journal-title":"Oral Oncol"},{"issue":"1","key":"11752_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02079-8","volume":"23","author":"X Xia","year":"2024","unstructured":"Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J et al (2024) Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer 23(1):175","journal-title":"Mol Cancer"},{"key":"11752_CR107","doi-asserted-by":"publisher","first-page":"618387","DOI":"10.3389\/fimmu.2020.618387","volume":"11","author":"L Lindo","year":"2021","unstructured":"Lindo L, Wilkinson LH, Hay KA (2021) Befriending the hostile tumor microenvironment in CAR T-cell therapy. Front Immunol 11:618387","journal-title":"Front Immunol"},{"issue":"5","key":"11752_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/cells14050320","volume":"14","author":"B Zhang","year":"2025","unstructured":"Zhang B, Wu J, Jiang H, Zhou M (2025) Strategies to overcome Antigen Heterogeneity in CAR-T cell therapy. Cells 14(5):320","journal-title":"Cells"},{"issue":"1","key":"11752_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-02719-0","volume":"13","author":"HS Budi","year":"2022","unstructured":"Budi HS, Ahmad FN, Achmad H, Ansari MJ, Mikhailova MV, Suksatan W et al (2022) Human epidermal growth factor receptor 2 [HER2]-specific chimeric antigen receptor [CAR] for tumor immunotherapy; recent progress. Stem Cell Res Ther 13(1):40","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"11752_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0758-x","volume":"12","author":"J Wei","year":"2019","unstructured":"Wei J, Han X, Bo J, Han W (2019) Target selection for CAR-T therapy. J Hematol Oncol 12(1):62","journal-title":"J Hematol Oncol"},{"issue":"7","key":"11752_CR111","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","volume":"12","author":"RM Young","year":"2022","unstructured":"Young RM, Engel NW, Uslu U, Wellhausen N, June CH (2022) Next-generation CAR T-cell therapies. Cancer Discov 12(7):1625\u20131633","journal-title":"Cancer Discov"},{"issue":"1","key":"11752_CR112","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL et al (2023) Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol 20(1):49\u201362","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"11752_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196124","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qin D, Shou AC, Liu Y, Wang Y, Zhou L (2023) Exploring CAR-T cell therapy side effects: mechanisms and management strategies. J Clin Med 12(19):6124","journal-title":"J Clin Med"},{"key":"11752_CR114","unstructured":"Shaikh S, Shaikh H. (2023) CART cell therapy toxicity. StatPearls [Internet]: StatPearls Publishing."},{"key":"11752_CR115","doi-asserted-by":"crossref","unstructured":"Castaneda-Puglianini O, Chavez JC. (2021) Assessing and management of neurotoxicity after CAR-T therapy in diffuse large B-cell lymphoma. 775-83.","DOI":"10.2147\/JBM.S281247"},{"key":"11752_CR116","doi-asserted-by":"publisher","first-page":"879608","DOI":"10.3389\/fimmu.2022.879608","volume":"13","author":"RC Sterner","year":"2022","unstructured":"Sterner RC, Sterner RM (2022) Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Front immunol 13:879608","journal-title":"Front immunol"},{"issue":"1","key":"11752_CR117","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W et al (2024) Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J hematol oncol 17(1):105","journal-title":"J hematol oncol"},{"issue":"10","key":"11752_CR118","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S (2024) CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell molecular immunol 21(10):1089\u20131108","journal-title":"Cell molecular immunol"},{"key":"11752_CR119","doi-asserted-by":"publisher","first-page":"1399544","DOI":"10.3389\/fonc.2024.1399544","volume":"14","author":"J Luo","year":"2024","unstructured":"Luo J, Zhang X (2024) Challenges and innovations in CAR-T cell therapy: a comprehensive analysis. Front Oncol 14:1399544","journal-title":"Front Oncol"},{"issue":"7949","key":"11752_CR120","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL (2023) CAR immune cells: design principles, resistance and the next generation. Nature 614(7949):635\u2013648","journal-title":"Nature"},{"key":"11752_CR121","doi-asserted-by":"crossref","unstructured":"Atar D, Ruoff L, Mast A-S, Krost S, Moustafa-Oglou M, Scheuermann S, et al. (2024) Rational combinatorial targeting by adapter CAR-T-cells [AdCAR-T] prevents antigen escape in acute myeloid leukemia. 38[10]:2183\u201395.","DOI":"10.1038\/s41375-024-02351-2"},{"issue":"9","key":"11752_CR122","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, Du H, Xu Y, Shou P, Zhou X, Fuc\u00e1 G et al (2021) Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nature cancer 2(9):904\u2013918","journal-title":"Nature cancer"},{"key":"11752_CR123","doi-asserted-by":"publisher","first-page":"1546172","DOI":"10.3389\/fimmu.2025.1546172","volume":"16","author":"S G\u00f3mez-Melero","year":"2025","unstructured":"G\u00f3mez-Melero S, Hassouneh F, Vallejo-Berm\u00fadez IM, Ag\u00fcera-Morales E, Solana R, Caballero-Villarraso J (2025) Tandem CAR-T cell therapy: recent advances and current challenges. Front Immunol 16:1546172","journal-title":"Front Immunol"},{"key":"11752_CR124","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coi.2016.02.006","volume":"40","author":"EA Zhukovsky","year":"2016","unstructured":"Zhukovsky EA, Morse RJ, Maus MV (2016) Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr opinion immunol 40:24\u201335","journal-title":"Curr opinion immunol"},{"issue":"4","key":"11752_CR125","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh M, Mansilla-Soto J, Rivi\u00e8re I, Sadelain MJ (2023) Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov 13(4):829\u2013843","journal-title":"Cancer Discov"},{"issue":"1","key":"11752_CR126","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han X, Wang Y, Wei J, Han WJ (2019) Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J Hematol Oncology 12(1):128","journal-title":"J Hematol Oncology"},{"issue":"7","key":"11752_CR127","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO (2023) Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics 15(7):1796","journal-title":"Pharmaceutics"},{"issue":"1","key":"11752_CR128","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40164-024-00570-y","volume":"13","author":"X Feng","year":"2024","unstructured":"Feng X, Li Z, Liu Y, Chen D, Zhou Z (2024) CRISPR\/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications. Exp Hematology Oncol 13(1):102","journal-title":"Exp Hematology Oncol"},{"issue":"12","key":"11752_CR129","doi-asserted-by":"publisher","first-page":"12133","DOI":"10.1007\/s11033-022-07880-6","volume":"49","author":"D Javaid","year":"2022","unstructured":"Javaid D, Ganie SY, Hajam YA, Reshi MS (2022) CRISPR\/Cas9 system: a reliable and facile genome editing tool in modern biology. Molecular Biol Reports 49(12):12133\u201312150","journal-title":"Molecular Biol Reports"},{"key":"11752_CR130","doi-asserted-by":"publisher","first-page":"1368732","DOI":"10.3389\/fonc.2024.1368732","volume":"14","author":"Y Lv","year":"2024","unstructured":"Lv Y, Luo X, Xie Z, Qiu J, Yang J, Deng Y et al (2024) Prospects and challenges of CAR-T cell therapy combined with ICIs. Front Oncol 14:1368732","journal-title":"Front Oncol"},{"key":"11752_CR131","doi-asserted-by":"publisher","first-page":"640082","DOI":"10.3389\/fimmu.2021.640082","volume":"12","author":"D Mart\u00ednez Bedoya","year":"2021","unstructured":"Mart\u00ednez Bedoya D, Dutoit V, Migliorini DJ (2021) Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma. Front immunol 12:640082","journal-title":"Front immunol"},{"issue":"21","key":"11752_CR132","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.3390\/cancers14215442","volume":"14","author":"J Rial Saborido","year":"2022","unstructured":"Rial Saborido J, V\u00f6lkl S, Aigner M, Mackensen A, Mougiakakos D (2022) Role of CAR T cell metabolism for therapeutic efficacy. Cancers 14(21):5442","journal-title":"Cancers"},{"key":"11752_CR133","doi-asserted-by":"publisher","first-page":"1462697","DOI":"10.3389\/fimmu.2024.1462697","volume":"15","author":"M Amiri","year":"2024","unstructured":"Amiri M, Moaveni AK, Majidi Zolbin M, Shademan B, Nourazarian A (2024) Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR\/Cas9. Front Immunol 15:1462697","journal-title":"Front Immunol"},{"issue":"1","key":"11752_CR134","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri A, Herbst F, Fraietta JA (2022) Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer 21(1):78","journal-title":"Mol Cancer"},{"key":"11752_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638186","volume":"16","author":"T Andreou","year":"2025","unstructured":"Andreou T, Neophytou C, Kalli M, Mpekris F, Stylianopoulos T (2025) Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling. Front Immunol 16:1638186","journal-title":"Front Immunol"},{"issue":"4","key":"11752_CR136","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","volume":"43","author":"U Uslu","year":"2025","unstructured":"Uslu U, June CH (2025) Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat Biotechnol 43(4):506\u2013515","journal-title":"Nat Biotechnol"},{"key":"11752_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2019.00160","volume":"6","author":"E Henke","year":"2020","unstructured":"Henke E, Nandigama R, Erg\u00fcn S (2020) Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci 6:160","journal-title":"Front Mol Biosci"},{"issue":"5","key":"11752_CR138","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES et al (2015) Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21(5):524\u2013529","journal-title":"Nat Med"},{"issue":"1","key":"11752_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00475-8","volume":"11","author":"S Wang","year":"2023","unstructured":"Wang S, Zhao X, Wu S, Cui D, Xu Z (2023) JBr. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomarker Research 11(1):34","journal-title":"Biomarker Research"},{"issue":"2","key":"11752_CR140","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32020079","volume":"32","author":"I Klabukov","year":"2025","unstructured":"Klabukov I, Kabakov AE, Yakimova A, Baranovskii D, Sosin D, Atiakshin D et al (2025) Tumor-associated extracellular matrix obstacles for CAR-T cell therapy: approaches to overcoming. Curr Oncol 32(2):79 (sss147.)","journal-title":"Curr Oncol"},{"key":"11752_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.971278","volume":"13","author":"W Donelan","year":"2022","unstructured":"Donelan W, Dominguez-Gutierrez PR, Kusmartsev S (2022) Deregulated hyaluronan metabolism in the tumor microenvironment drives cancer inflammation and tumor-associated immune suppression. Front Immunol 13:971278","journal-title":"Front Immunol"},{"key":"11752_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.onano.2022.100083","volume":"8","author":"K Niveria","year":"2022","unstructured":"Niveria K, Yadav M, Dangi K, Verma AK (2022) Overcoming challenges to enable targeting of metastatic breast cancer tumour microenvironment with nano-therapeutics: current status and future perspectives. OpenNano 8:100083","journal-title":"OpenNano"},{"issue":"3","key":"11752_CR143","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li LJ (2020) PD-1\/PD-L1 pathway: current researches in cancer. Am j cancer res. 10(3):727","journal-title":"Am j cancer res."},{"issue":"1","key":"11752_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02386-8","volume":"24","author":"SS Azeez","year":"2025","unstructured":"Azeez SS, Yashooa RK, Smail SW, Salihi A, Ali AS, Mamand S et al (2025) Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives. Mol Cancer 24(1):191","journal-title":"Mol Cancer"},{"issue":"1","key":"11752_CR145","first-page":"82","volume":"22","author":"L Hovhannisyan","year":"2023","unstructured":"Hovhannisyan L, Riether C, Aebersold DM, Medov\u00e1 M, Zimmer Y (2023) CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks. JMc 22(1):82","journal-title":"JMc"},{"issue":"1","key":"11752_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47799-z","volume":"15","author":"I Andreu-Saumell","year":"2024","unstructured":"Andreu-Saumell I, Rodriguez-Garcia A, M\u00fchlgrabner V, Gimenez-Alejandre M, Marzal B, Castellsagu\u00e9 J et al (2024) CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition. Nat Commun 15(1):3552","journal-title":"Nat Commun"},{"key":"11752_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1140541","volume":"14","author":"AX Wang","year":"2023","unstructured":"Wang AX, Ong XJ, D\u2019Souza C, Neeson PJ, Zhu JJ (2023) Combining chemotherapy with CAR-T cell therapy in treating solid tumors. Front Immunol 14:1140541","journal-title":"Front Immunol"},{"issue":"9","key":"11752_CR148","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.ymthe.2021.08.003","volume":"29","author":"B Akbari","year":"2021","unstructured":"Akbari B, Ghahri-Saremi N, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR (2021) Epigenetic strategies to boost CAR T cell therapy. Mol Ther 29(9):2640\u20132659","journal-title":"Mol Ther"},{"issue":"1","key":"11752_CR149","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2158013","volume":"12","author":"P-A Laurent","year":"2023","unstructured":"Laurent P-A, Morel D, Meziani L, Depil S, Deutsch E (2023) JO. Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors. OncoImmunology 12(1):2158013","journal-title":"OncoImmunology"},{"issue":"1","key":"11752_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02778-6","volume":"22","author":"M Al-Haideri","year":"2022","unstructured":"Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT et al (2022) CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int 22(1):365","journal-title":"Cancer Cell Int"},{"issue":"1","key":"11752_CR151","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J (2023) Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol 12(1):14","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"11752_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101079","volume":"14","author":"PS Kozani","year":"2021","unstructured":"Kozani PS, Kozani PS, Rahbarizadeh F (2021) Novel antigens of CAR T cell therapy: New roads; old destination. Translational Oncology 14(7):101079","journal-title":"Translational Oncology"},{"issue":"7","key":"11752_CR153","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/stem.2039","volume":"33","author":"Q Pan","year":"2015","unstructured":"Pan Q, Li Q, Liu S, Ning N, Zhang X, Xu Y et al (2015) Concise review: targeting cancer stem cells using immunologic approaches. Stem Cells 33(7):2085\u20132092","journal-title":"Stem Cells"},{"key":"11752_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1378944","volume":"15","author":"L Levstek","year":"2024","unstructured":"Levstek L, Jan\u017ei\u010d L, Ihan A, Kopitar AN (2024) Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives. Front Immunol 15:1378944","journal-title":"Front Immunol"},{"key":"11752_CR155","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","volume":"17","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Jiang C, Liu Z, Yang M, Tang X, Wang Y et al (2020) B7-H3-targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors. Molecular Therapy - Oncolytics 17:180\u2013189","journal-title":"Molecular Therapy - Oncolytics"},{"key":"11752_CR156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1110028","volume":"14","author":"H Xu","year":"2023","unstructured":"Xu H, Li N, Wang G, Cao Y (2023) Predictive short\/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed\/refractory B-cell lymphomas. Front Immunol 14:1110028","journal-title":"Front Immunol"},{"issue":"03n04","key":"11752_CR157","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1142\/S2339547818300020","volume":"6","author":"P Krzyszczyk","year":"2018","unstructured":"Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M et al (2018) The growing role of precision and personalized medicine for cancer treatment. Technology 6(03n04):79\u2013100","journal-title":"Technology"},{"issue":"3","key":"11752_CR158","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008450","volume":"12","author":"H Zou","year":"2024","unstructured":"Zou H, Liu W, Wang X, Wang Y, Wang C, Qiu C et al (2024) Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. J Immunother Cancer 12(3):e008450","journal-title":"J Immunother Cancer"},{"key":"11752_CR159","doi-asserted-by":"crossref","unstructured":"Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, et al. (2021) Chimeric antigen receptor [CAR] T\u2010cell therapy for people with relapsed or refractory diffuse large B\u2010cell lymphoma 2021(9)","DOI":"10.1002\/14651858.CD013365.pub2"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11752-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11752-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11752-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:03:23Z","timestamp":1775563403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11752-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":159,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11752"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11752-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This manuscript is a narrative review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no conflict of interest to report.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Consent for publication was obtained from all the authors involved in this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"We, all the authors, declare that no generative AI or AI-assisted technologies have been utilized during drafting this manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Generative AI or AI-assisted technologies"}},{"value":"We confirm that EndNote Reference Management Software, Clarivate, a freely available software application was utilized for reference management, and BioRender, another freely available tool, was employed for the creation of figures in this manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}],"article-number":"593"}}